Data-driven Site Negotiations:
Fast Track to Fair Market Value (FMV)
About this webinar
With investigator payments constituting as much as 50 percent of a study’s overall costs, it’s important to understand and manage the key drivers of these costs. By doing so, sponsors and CROs can benefit from accelerated negotiations, reduced compliance risk and better site relationships.
Join us for this one-hour webinar session to hear:
- A description of the primary drivers of site costs, with examples;
- An in-depth discussion of the correlation and impact of study complexity; and
- Case studies highlighting the benefits of better study planning.
Who should attend
- Clinical Operations
- Clinical Outsourcing
- Finance & Budgeting
- R&D
- Senior Management
Featured Speakers
Stella Stergiopoulos
Stella is a project director at Tuft’s Center for the Study of Drug Development. She has been with CSDD for approximately 5 years and recently co-authored on article in the American Journal of Therapeutics entitled, “Quantifying the Magnitude and Cost of Collecting Extraneous Protocol Data”.
Vic DeSario
Vic is Director of Trial Planning Solutions at Medidata. In this role he interacts with clinical trial sponsors, helping them optimize their clinical spending and related processes. He has been in the life sciences industry for 13 years preceded by another 15 in healthcare.
Partners for this event
Medidata Solutions
Medidata Solutions is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of our global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.
Tufts
The Tufts Center for the Study of Drug Development at Tufts University provides strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of pharmaceutical development, review, and utilization. Tufts CSDD, based in Boston, conducts a wide range of in-depth analyses on pharmaceutical issues and hosts symposia, workshops, and public forums, and publishes Tufts CSDD Impact Reports, a bi-monthly newsletter providing analysis and insight into critical drug development issues.
Related webinars
More from Medidata Solutions.
CNS Trials with Sensors to Capture Patient Data
Efficient eCOA Implementation in Clinical Trials
Digitizing Alzheimer’s Disease Trials with eCOA and Digital Cognitive Assessments
Risk-Based Quality Management (RBQM): The Connective Tissue for Clinical Data Quality
Improving Patient Experience: Optimizing Patient Payment Systems Through Collaboration
Streamlining Clinical Trial Imaging Workflows: From Collection to Completion
Outsourcing Site Payments from the Sponsors’ Perspective
Accelerating Decentralized Trials with a Unified Approach to Wearable Sensors
Preparing for ICH E6 (R3) Good Clinical Practice Changes
Imaging AI and Machine Learning – Beyond the Hype
Site Quality Management to Optimize Risk-Based and Centralized Monitoring
Streamlining the Site Budgeting and Payment Process
